Your browser doesn't support javascript.
Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome.
Streng, Bianca M M; Bont, Marin; Delemarre, Eveline M; Binnendijk, Rob S; Smit, Gaby; den Hartog, Gerco; Coppus, Antonia M W; de Vries, Esther; Weijerman, Michel E; Lamberts, Regina; de Graaf, Gert; van der Klis, Fiona R; Vidarsson, Gestur; Rave, Neele; Bont, Louis J; Wildenbeest, Joanne G.
  • Streng BMM; Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Bont M; Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Delemarre EM; Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Binnendijk RS; Center of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Smit G; Laboratory for Vaccine-Preventable Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
  • den Hartog G; Laboratory for Vaccine-Preventable Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
  • Coppus AMW; Laboratory for Vaccine-Preventable Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
  • de Vries E; Department for Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Weijerman ME; Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands.
  • Lamberts R; Jeroen Bosch Academy Research, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
  • de Graaf G; Department of Pediatrics, Alrijne Hospital, Leiderdorp, The Netherlands.
  • van der Klis FR; Department of Pediatrics, Alrijne Hospital, Leiderdorp, The Netherlands.
  • Vidarsson G; Foundation Stichting Down Syndroom, Meppel, The Netherlands.
  • Rave N; Laboratory for Vaccine-Preventable Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
  • Bont LJ; Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Wildenbeest JG; Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.
J Infect Dis ; 226(4): 673-677, 2022 09 04.
Article in English | MEDLINE | ID: covidwho-2017956
ABSTRACT
The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION NCT05145348.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Down Syndrome / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Down Syndrome / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis